Renaissance and CyberSmart Partner to Deliver Complete Cyber Confidence for SMEs
Renaissance has announced a strategic partnership with CyberSmart, a UK-based cybersecurity provider focused on delivering continuous protection, compliance, and cyber risk management for small and medium-sized enterprises (SMEs).
Signaloid announces preview of new ASIC targeted at physical AI and robotics applications
Signaloid previews a new ASIC purpose-built for physical AI and robotics workloads.
Verinnogen raises £500k to advance cancer drug development
CPI Enterprises, part of the High Value Manufacturing Catapult, has invested £500,000 in Cambridge-based life sciences company Verinnogen to support the development of a novel technology designed to improve the accuracy and reliability of cancer drug development.
Rethinking Clinical Trials with Synthetic Control Arms
Kiril Kirov from Qureight discusses how synthetic control arms offer an alternative to conventional control groups and improve clinical trial design.
Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models
Ambient-temperature preservation solution enables reliable storage and shipment of organoids and spheroids, to support growing adoption of New Approach Methodologies.
10 UK startups revolutionising patient care through digital health
The NHS is one of the world’s most ambitious public health systems, but it faces mounting pressures from an ageing population, chronic illnesses, and limited public funding.
Dorset bird song recordings offer new insight into diversity
Cutting-edge sound technology has laid bare a stark contrast in bird life between conventional and regenerative farming in just six days.
Healx AI: 10 Essential Facts About the Cambridge Rare Disease Drug Discovery Pioneer
Healx, a leading UK artificial intelligence-powered biotech company, continues to reshape drug discovery for rare diseases in 2026, leveraging advanced machine learning to accelerate treatments for conditions that affect millions but often lack approved therapies.
Patients Know Best and Heartfelt Technologies collaborate to accelerate clinical trial recruitment
Patients Know Best has collaborated with Heartfelt Technologies to automate and accelerate clinical trial recruitment, by taking a digital-first approach to patients.
Bristol spin-out Albotherm awarded its first UK patent
A University of Bristol spin-out which has developed an innovative temperature-responsive coating for greenhouses and buildings has been awarded its first UK patent.
Abselion Appoints Dale Gordon as Chair
Bioprocessing leader to drive continued commercial development and international expansion.
Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis
Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis.
ZeroRISC Delivers Production-Grade Post-Quantum Cryptography for Open Silicon
ZeroRISC has delivered a production-grade, open-source cryptographic hardware and software stack designed to secure systems in a post-quantum computing era, stemming from a multi-year collaboration with the Max Planck Institute for Security and Privacy and the Institute of Information Science at Academia Sinica.
Engine vroom as Abselion opens US base
Abselion, a life sciences tech company anchored in Cambridge UK and focused on simplifying biomolecule quantification, has established a US subsidiary at The Engine in Cambridge, MA.
CamGene Therapeutics wins HCR Law Impact55 accolade
CamGene Therapeutics, based in Hauxton, has won the HCR Law Impact55 title. The company uses biotechnology to develop medicines that aim to treat hearing loss rather than simply manage it.
Eco-Inject raises £5.2m to scale reinvented autoinjector
Eco-Inject, a Cambridge Science Park medical device company reinventing the autoinjector, has completed a £5.2 million equity raise led by British investment syndicate, Adjuvo and is targeting a significant slice of a huge international market.
Axol Bioscience makes third acquisition in five years
Axol Bioscience, a life science business headquartered in Edinburgh but with facilities at Babraham Research Campus in Cambridge, has made a key acquisition not long after raising $2.8 million.
UK medtech Orthofuse raises £2.2M for 3D-printed implants that surgeons can tweak
London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
Albotherm, CPI lead £2 million collaborative project to scale low-emissions greenhouse technology for UK growers
London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
Qkine Limited and Akron Bio Announce Strategic Partnership
Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics.